Longitudinal Plasma Kallikrein Levels and Their Association With the Risk of Cardiovascular Disease Outcomes in Type 1 Diabetes in DCCT/EDIC

We determined the relationship between plasma kallikrein and cardiovascular disease (CVD) outcomes as well as major adverse cardiovascular events (MACE) in the Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) cohort of type 1 diabetes (T1D). Plasma kallikrein levels were measured longitudinally in 693 subjects at DCCT baseline (1983–1989), midpoint (1988–1991), and end (1993) and at EDIC years 4–6 (1997–1999), 8–10 (2001–2003), and 11–13 (2004–2006). Cox proportional hazards regression models assessed the association between plasma kallikrein levels and the risk of CVD. In unadjusted models, higher plasma kallikrein levels were associated with higher risk of any CVD during DCCT/EDIC (hazard ratio [HR] = 1.16 per 20 nmol/L higher levels of plasma kallikrein; P = 0.0177) as well as over the EDIC-only period (HR = 1.22; P = 0.0024). The association between plasma kallikrein levels and the risk of any CVD remained significant during the EDIC follow-up after adjustment for age and mean HbA1c (HR = 1.20; P = 0.0082) and in the fully adjusted model for other CVD risk factors (HR = 1.17; P = 0.0330). For MACE, higher plasma kallikrein levels were associated with higher risk in the unadjusted (HR = 1.25; P = 0.0145), minimally adjusted (HR = 1.23; P = 0.0417, and fully adjusted (HR = 1.27; P = 0.0328) models for EDIC only. These novel findings indicate that plasma kallikrein level associates with the risk of any CVD and MACE in T1D individuals.

[1]  J. Lachin,et al.  Mediation of the Effect of Glycemia on the Risk of CVD Outcomes in Type 1 Diabetes: The DCCT/EDIC Study , 2019, Diabetes Care.

[2]  J. Moriya.  Critical roles of inflammation in atherosclerosis. , 2019, Journal of cardiology.

[3]  A. Mansur,et al.  Genetic associations of bradykinin type 2 receptor, alpha-adrenoceptors and endothelial nitric oxide synthase with blood pressure and left ventricular mass in outpatients without overt heart disease , 2018, International journal of cardiology. Heart & vasculature.

[4]  T. Renné,et al.  The plasma contact system, a protease cascade at the nexus of inflammation, coagulation and immunity. , 2017, Biochimica et biophysica acta. Molecular cell research.

[5]  P. Libby,et al.  Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease , 2017, The New England journal of medicine.

[6]  S. Genuth,et al.  Coprogression of Cardiovascular Risk Factors in Type 1 Diabetes During 30 Years of Follow-up in the DCCT/EDIC Study , 2016, Diabetes Care.

[7]  A. Schmaier,et al.  A Cross-sectional Study of KLKB1 and PRCP Polymorphisms in Patient Samples with Cardiovascular Disease , 2016, Front. Med..

[8]  A. Schmaier,et al.  Plasma Prekallikrein Is Associated With Carotid Intima-Media Thickness in Type 1 Diabetes , 2015, Diabetes.

[9]  K. Bønaa,et al.  Clinically Significant Novel Biomarkers for Prediction of First Ever Myocardial Infarction: The Tromsø Study , 2014, Circulation. Cardiovascular genetics.

[10]  K. Khunti,et al.  Hypoglycemia and Risk of Cardiovascular Disease and All-Cause Mortality in Insulin-Treated People With Type 1 and Type 2 Diabetes: A Cohort Study , 2014, Diabetes Care.

[11]  C. Maggi,et al.  Antagonism of Bradykinin B2 Receptor Prevents Inflammatory Responses in Human Endothelial Cells by Quenching the NF-kB Pathway Activation , 2014, PloS one.

[12]  D. Nathan,et al.  Update on Cardiovascular Outcomes at 30 Years of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study , 2013, Diabetes Care.

[13]  T. Renné,et al.  Plasma kallikrein: the bradykinin-producing enzyme , 2013, Thrombosis and Haemostasis.

[14]  B. Monia,et al.  Selective depletion of plasma prekallikrein or coagulation factor XII inhibits thrombosis in mice without increased risk of bleeding. , 2011, Blood.

[15]  L. Luttrell,et al.  Plasma Kallikrein Promotes Epidermal Growth Factor Receptor Transactivation and Signaling in Vascular Smooth Muscle through Direct Activation of Protease-activated Receptors* , 2010, The Journal of Biological Chemistry.

[16]  S. Kelsey,et al.  Cause-Specific Mortality Trends in a Large Population-Based Cohort With Long-Standing Childhood-Onset Type 1 Diabetes , 2010, Diabetes.

[17]  Kestutis G. Bendinskas,et al.  Plasma prekallikrein levels are positively associated with circulating lipid levels and the metabolic syndrome in children. , 2010, Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme.

[18]  C. Hack,et al.  The plasma kallikrein–kinin system and risk of cardiovascular disease in men , 2007, Journal of thrombosis and haemostasis : JTH.

[19]  B. Wang,et al.  Mechanisms through which bradykinin promotes glomerular injury in diabetes. , 2005, American journal of physiology. Renal physiology.

[20]  E. Hawe,et al.  Variation in bradykinin receptor genes increases the cardiovascular risk associated with hypertension. , 2003, European heart journal.

[21]  A. Schmaier,et al.  Plasma prekallikrein: a risk marker for hypertension and nephropathy in type 1 diabetes. , 2003, Diabetes.

[22]  B. Lämmle,et al.  Elevated levels of plasma prekallikrein, high molecular weight kininogen and factor XI in coronary heart disease. , 2002, Atherosclerosis.

[23]  W. Tamborlane,et al.  Epidemiology of Diabetes Interventions and Complications (EDIC). Design, implementation, and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial cohort. , 1999, Diabetes care.

[24]  Lipid and Lipoprotein Levels in Patients With IDDM: Diabetes Control and Complication Trial Experience , 1992, Diabetes Care.

[25]  The Diabetes Control and Complications Trial (DCCT): Design and Methodologic Considerations for the Feasibility Phase , 1986, Diabetes.